Details

Autor(en) / Beteiligte

• Jacques, Carine
• Jamin, Emilien L.
• Jouanin, Isabelle
• Canlet, Cécile
• Tremblay-Franco, Marie
• Martin, Jean-François
• Zalko, Daniel
• Brunel, Yves
• Bessou-Touya, Sandrine
• Debrauwer, Laurent
• Ferret, Pierre-Jacques
• Duplan, Hélène

Titel

Safety assessment of cosmetics by read across applied to metabolomics data of in vitro skin and liver models

Ist Teil von

• Archives of toxicology, 2021-10, Vol.95 (10), p.3303-3322

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2021

Quelle

SpringerLink

Beschreibungen/Notizen

• As a result of the cosmetics testing ban, safety evaluations of cosmetics ingredients must now be conducted using animal-free methods. A common approach is read across, which is mainly based on structural similarities but can also be conducted using biological endpoints. Here, metabolomics was used to assess biological effects to enable a read across between a candidate cosmetic ingredient, DIV665, only studied using in vitro assays, and a structurally similar reference compound, PA102, previously investigated using traditional in vivo toxicity methods. The (1) cutaneous distribution after topical application, (2) skin metabolism, (3) liver metabolism and (4) effect on the intracellular metabolomic profiles of in vitro skin and hepatic models, SkinEthic ® RHE model and HepaRG ® cells were investigated. The compounds exhibited similar skin penetration and skin and liver metabolism, with small differences attributed to their physicochemical properties. The effects of both compounds on the metabolome of RHE and HepaRG ® cells were similarly small, both in terms of the metabolites modulated and the magnitude of changes. The patterns of metabolome changes did not fit with any known signature relating to a mode of action known to be linked to liver toxicity e.g. modification of the Krebs cycle, urea synthesis and lipid metabolism, were more reflective of transient adaptive responses. Overall, these studies indicate that PA102 is biologically similar to DIV665, allowing read across of safety endpoints, such as in vivo sub-chronic (but not reproduction toxicity) studies, for the former to be applied to DIV665. Based on this, in the absence of animal data (which is prohibited for new chemicals), it could be concluded that DIV665 applied according to the consumer topical use scenario, is similar to PA102, and is predicted to exhibit low local skin and systemic toxicity.